Home/PharmaCyte Biotech/Joshua N. Silverman

JN

Joshua N. Silverman

Interim Chief Executive Officer, President, and Director

PharmaCyte Biotech

Therapeutic Areas

Oncology Metabolic Disease

PharmaCyte Biotech Pipeline

Drug	Indication	Phase
Cell-in-a-Box® + Ifosfamide	Locally Advanced Pancreatic Cancer (LAPC)	Phase 2b
Cell-in-a-Box® Insulin-Producing Cells	Type 1 & Insulin-dependent Type 2 Diabetes	Preclinical

Leadership Team at PharmaCyte Biotech

Carlos A. Trujillo

Chief Financial Officer

Dr. José Iglesias

Consulting Chief Medical Officer

Dr. Michael M. Abecassis

View full PharmaCyte Biotech profile